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Background: Prompt diagnosis and effective treatment are considered the cornerstones of malaria control and
artemisinin-based combination therapy (ACT) is currently the main anti-malarial drugs used for case management.
After deployment of ACT due to widespread parasite resistance to the cheap and widely used anti-malarial drugs,
chloroquine and sulphadoxine/pyrimethamine, the World Health Organization recommends regular surveillance to
monitor the efficacy of the new drugs. The present paper assessed the implementation of anti-malarial efficacy testing
for monitoring the therapeutic efficacy of ACT for treatment of uncomplicated malaria in Tanzania before and after policy
changes in 2006.
Methods: A literature search was performed for published clinical trials conducted in Tanzania from 2001 to 2014. It
focused on studies which assessed at least one form of ACT for treatment of uncomplicated falciparum malaria in
children less than 10 years and reported efficacy and safety of the tested anti-malarials. References were imported into
the Endnote library and duplicates removed. An electronic matrix was developed in Microsoft Excel followed by full text
review with predetermined criteria. Studies were independently assessed and information related to ACT efficacy and
safety extracted.
Results: Nine papers were selected from 125 papers screened. The efficacy of both artemether-lumefantrine (AL) and
artesunate-amodiaquine (AS + AQ) against uncomplicated P. falciparum infections in Tanzania was high with PCR-
corrected cure rates on day 28 of 91-100% and 88-93.8%, respectively. The highest day-3 parasite positivity rate was 1.4%.
Adverse events ranged from mild to serious but were not directly attributed to the drugs.
Conclusion: ACT is efficacious and safe for treatment of uncomplicated malaria in Tanzania. However, few trials were
conducted in Tanzania before and after policy changes in 2006 and thus more surveillance should be urgently
undertaken to detect future changes in parasite sensitivity to ACT.
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Malaria is by far the most important parasitic disease in
Tanzania and in other tropical countries, causing loss of
life and morbidity with more than three billion people at
risk globally [1]. Prompt diagnosis and effective treat-
ment are considered the cornerstones of malaria control
[2-4]. However, resistance of malaria parasites to the
cheap and commonly used anti-malarials has become a
major challenge to malaria control. Worldwide resist-
ance of Plasmodium falciparum to chloroquine (CQ)
and the rapid spread of resistance to sulphadoxine-
pyrimethamine (SP) prompted the introduction of arte-
misinin combination therapy (ACT). In 2001, a World
Health Organization (WHO) expert panel recommended
use of ACT for treatment of uncomplicated falciparum
malaria in all endemic countries [5].
The combination therapy involves simultaneous use of
two or more blood schizonticidal drugs with independent
modes of action and different biochemical targets in the
parasite, a mechanism which delays development of para-
site resistance [6,7]. ACT can be either fixed-combination
medicinal products, in which different drugs are co-
formulated in the same tablets or capsules, or multiple drug
therapy, in which the components are co-administered in
separate tablets or capsules. The short-lived artemisinin-
derivative component of ACT causes rapid and effective re-
duction of parasite biomass and gametocyte carriage, while
the partner drug with a longer duration of action clears the
remaining parasite biomass. The two drugs work together
to achieve effective clinical and parasitological cure and
protect each other from development of resistance by P.
falciparum [5].
The current recommended combinations are artemether-
lumefantrine (AL), artesunate-amodiaquine (AS +AQ),
artesunate-mefloquine (AS +MQ), dihydroartemisinin-
piperaquine (DHA+ PQ), and artesunate-sulphadoxine/
pyrimethamine (AS + SP) [8]. Artemisinin-naphthoquine
combination (ARCO™) has also been tested and has shown
some potentials as a new generation ACT for the treatment
of uncomplicated malaria, but it is still under further clin-
ical evaluation [9]. Prior to policy changes, malaria-endemic
countries had to choose among the above combinations
based on different factors, such as price, level of parasite re-
sistance to the partner drug in the local parasite population
and the capacity of the country to sustainably supply the
anti-malarials [8,10-12]. Thus, AL and AS +AQ are the
main ACT that have been widely deployed in majority of
the African countries [13].
Parasite resistance to anti-malarials is of great concern
in the efforts to control malaria worldwide. The parasites
develop resistance by initially becoming tolerant to the
drugs before they become fully resistant. The resistant
parasites have an ability to survive under therapeutic
levels of anti-malarial drugs which would otherwise killboth sensitive and tolerant parasites [14]. Parasite resist-
ance to the anti-malarials can be assessed through
in vivo, in vitro tests, analysis of known molecular
markers of parasite resistance and by measurement of
drug levels among patients treated with the respective
anti-malarials [15-18]. Measures such as parasite clear-
ance time, fever clearance time or gametocyte clearance
time in in vivo and in vitro assays are used to indirectly
detect any variation in parasite sensitivity thereby facili-
tating early warning in case of emergence of tolerance or
resistance [19-21].
In vivo response of patients to treatments provides
more information to clinicians and policy makers and is
considered the gold standard for assessing anti-malarial
efficacy. However, therapeutic efficacy must be interpreted
as an interaction between the host factors (e.g., age, im-
munity and pharmacogenetics), the parasite factors (e.g.,
biomass, resistance) and the drug factors (e.g., pharmacoki-
netic properties, drug quality etc.) [17]. In vitro and mo-
lecular studies on the other hand, are useful in providing
addition information on the parasite susceptibility without
confounding effects of host factors although it is difficult to
judge their clinical relevance [17]. It is only recently that
K13-propeller polymorphism has been documented as a
molecular marker for monitoring artemisinin resistance
[22] and simpler genotyping protocols will be required be-
fore it can be fully adopted as a routine surveillance tool in
most endemic countries with limited technical and infra-
structural resources. Thus, effective monitoring of ACT has
been and will continue to rely largely on in vivo studies
with adequate follow-up. However, in vivo efficacy studies
have logistics and cost implications which have limited their
regular implementation.
WHO recommends regular efficacy testing for monitor-
ing the efficacy of anti-malarials [2,8,23]. In Tanzania, the
national malaria control programme (NMCP), in collabor-
ation with its partners, including research institutions,
medical universities, WHO country office and others, in-
cluding funding agencies, have been conducting regular
therapeutic efficacy trials (TETs). The efforts of the NMCP
to ensure regular TETs have also been complemented by
trials conducted by independent researchers. Thus, regular
implementation of TETs is one of the priority activities of
the Tanzania NMCP, which provides useful data for moni-
toring the efficacy of ACT and detecting emergence of
drug tolerance/resistance to these and other anti-malarials
used in the country. The findings of these studies have
been used to guide the NMCP in reviewing and changing
anti-malarial drug policy in the past [24,25].
Tanzania changed its malaria treatment policy from
CQ to SP monotherapy as the first-line drug for the
treatment of uncomplicated malaria in 2001 [25]. How-
ever, shortly after its introduction, P. falciparum resist-
ance to SP was reported [26,27] and this forced the
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duce ACT. Studies conducted in 2004 in Tanzania indi-
cated that the mean SP treatment failure was as high as
25.5% [28] which was higher than the WHO recom-
mended cut-off failure rate (15%), above which policy
changes have to be made [2,29]. Whereas Zanzibar
adopted AS + AQ as first-line treatment in November
2001 [30], Tanzania mainland adopted AL as first-line
anti-malarial treatment of uncomplicated falciparum
malaria in November 2006 and became fully rolled out
in January 2007 [24].
Unfortunately, artemisinin-resistant field isolates have
been reported recently in four countries of Southeast
Asia (Cambodia, Myanmar, Thailand, and Vietnam) and
threatens the current progress in controlling the disease
[1,2,19]. There is a potential for such isolates to spread
to other malaria-endemic regions, including sub-Saharan
countries (SSA) as happened with previous anti-malarials
[31,32], and such parasites might be extremely difficult to
control. Such threat underscores the importance of inten-
sive surveillance of artemisinin resistance to prevent the
spread of resistance to other countries, as recommended
within the WHO Global Plan for artemisinin resistance
containment (GPARC) [23]. Such surveillance facilitates
early detection of emergence and spread of tolerance/re-
sistance to ACT and provides evidence for formulating
mitigation and containment strategies as recommended
by WHO [23,33], thus helping to safeguard the long-term
usefulness of these drugs.
The present paper reviewed the implementation of
in vivo efficacy testing in Tanzania before and after de-
ployment of ACT in order to monitor the efficacy of
ACT for the treatment of uncomplicated malaria. The
paper compares the cure rates, parasite clearance and
fever clearance times and safety data reported in clin-
ical trials involving ACT in Tanzania that were pub-
lished between 2001 and 2014. It provides updates on
country-specific performance of ACT after its wide-
scale deployment for treating uncomplicated falciparum
malaria.
Methods
Published literature was searched and it involved papers
published from January 2001 to August 2014. English
language articles indexed in PubMed were searched
using search terms: ‘Tanzania AND malaria AND
artemether-lumefantrine’, ‘Tanzania AND malaria AND
artesunate-amodiaquine’, ‘Tanzania AND malaria AND
artesunate-mefloquine’, ‘Tanzania AND malaria AND
dihydroartemisinin-piperaquine’ and ‘Tanzania AND
malaria AND artesunate-sulphadoxine-pyrimethamine’.
PubMed was used for primary search but in addition,
Google Scholar, the Worldwide Antimalarial Resistance
Network (WWARN) standardized analyses of ACTefficacy data repository and the African Journals Online
(AJOL) were used to confirm that no study was missed.
Inclusion criteria were clinical trials conducted in
Tanzania between 2001 and 2014 and involved at least
one ACT for treatment of uncomplicated falciparum
malaria. The studies should have reported the efficacy
and/or safety of the tested drugs. The starting year (i.e.,
2001) was purposely chosen because that was the year
when WHO advocated use of ACT for treating uncompli-
cated falciparum malaria [5]. References were imported
into the Endnote library and duplicates removed. An elec-
tronic matrix was developed in Microsoft Excel followed
by full text review with predetermined criteria. The se-
lected studies were each given an identification number,
independently assessed for key information on efficacy
and safety of ACT, which was extracted and summarized
in tables and texts.
Results
Literature search yielded 126 records, and 21 of these
were duplicate records which were removed. The titles
and abstracts of the remaining records (105) were
screened based on the inclusion criteria and 11 articles
qualified for a full-text review. From the review, two
additional papers were from multicentre trials across Africa,
which partly included Tanzania, and these were also re-
moved. Only nine papers were left and fully reviewed as
summarized in Figure 1.
Studies conducted to test the efficacy of ACT in Tanzania
Before and after the official adoption of ACT for treat-
ment of uncomplicated malaria in Tanzania in 2007 [24],
nine clinical trials were conducted in the country to as-
sess the efficacy and/or safety of ACT for treatment of
uncomplicated falciparum malaria (Table 1). All except
three studies were conducted in the eastern part of
Tanzania, with only one study from Zanzibar (Figure 2).
Of the nine studies, three were conducted before the
official adoption of ACT in Tanzania while the other
six were undertaken thereafter (Table 1). All of the nine
trials included AL testing, while five of these tested AL
alone [34-38], three (37.5%) tested AL with AS + AQ
[30,39,40], and one trial tested AL with azithromycin
(AZ) [41]. Six of the trials that tested AL were random-
ized trials with more than one arm (Table 1).
Treatment outcome in studies that reported the efficacy
of ACT in Tanzania
For the trials that tested AL, the reported PCR-corrected
cure rates ranged from 91 to 100% (Table 2). The highest
cure rate (100%) was reported by the studies conducted in
Kyela in 2004, Tabora in 2011 and Muheza in 2013, while
the lowest (91%) was reported in Muheza in 2008. PCR-
corrected cure rates of AS +AQ ranged from 88.8 to
Figure 1 Flow diagram for the literature search
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was 68%. For the studies that tested AL when adminis-
tered under supervision or unsupervised, the cure rates
were comparable in the two groups. Although the study
that tested the efficacy of AL when given unsupervised re-
ported that more than half of the patients had recurrent
infections within the 42-day follow-up period, the majority
of these were due to re-infections and the cure rate was
not significantly different when compared to the super-
vised arm. Studies that compared the efficacy of AL and
AS +AQ showed a significantly lower risk of re-infection
after treatment with AL than after treatment with AS +
AQ [30,40].
Fever, parasite and gametocyte clearance in studies that
reported efficacy of ACT in Tanzania
Among the five supervised trials that reported fever
clearance, more than 80 and 79% of the patients cleared
fever by day 1 post-treatment with AL and AS + AQ, re-
spectively. None of the patients had fever on day 3
(Table 3). Among the five studies that reported parasiteclearance, two studies showed day 3 parasitaemic cases
of 1.1 and 1.4% (Table 3).
In the present review, four papers reported gametocyte
carriage [30,34,37,40] and the proportion of patients
with gametocytes was significantly reduced from that re-
corded during enrolment compared to what was re-
ported after treatment with AL or AS + AQ. Joseph et al.
[34] showed an unusual increase in gametocytes in one
patient treated with AL, from four on day-0 to 68 sexual
parasites per 500 leucocytes on day-2.
Day-7 plasma lumefantrine levels
Three studies measured the median day-7 lumefantrine
levels [34,36,37] and one of these showed that the median
plasma lumefantrine concentration was significantly
higher in the supervised than in the unsupervised group
(P <0.001) [35]. Furthermore, the median day-7 plasma
lumefantrine concentration was significantly lower in pa-
tients with recrudescence compared to those with re-
infections or no parasite re-appearance [38]. It was further
shown that lumefantrine concentration at day 7 tended to
Table 1 Study design and baseline characteristics of efficacy trials that assessed AL and AS + AQ










































26 Muheza Yes, four arms 515 28 ≥2,000 18,920 No
TZ003_AL Kabanywanyi
et al. [39]





2004 7 Kilombero Yes, four arms 76 28 2,000-200,000 49,348 Yes
TZ004_AL Sykes et al.
[41]





2008 7 Muheza Yes, two arms 129 42 2,000-200,000 20,960** Partial




12 Bagamoyo Yes, two arms 180 56 2,000-200,000 41,885 Yes




12 Bagamoyo Yes, two arms 179 56 2,000-200,000 38,272 No
TZ006_AL Ngasala et al.
[37]





12 Mwanza No, single arm 108 28 2,000-200,000 5,608 Yes
TZ008_AL Joseph et al.
[34]
2011 3 Tabora No, single arm 20 28 2,000-200,000 39,400 Partial
TZ009_AL*** Shayo et al.
[38]
2013 2 Muheza No, single arm 88 28 250-200,000 18,603 Yes
Doses of AL were given twice a day for three days; Doses of AS + AQ were given once a day for three days;
TZ005_AL was the same study split into supervised and unsupervised*arm; NR = Not reported, Pf-GMPD = P. falciparum geometric mean parasite density of asexual
parasites per microlitre of blood. **median parasite counts (asexual parasites per microlitre of blood) reported
***The study was conducted after malaria transmission had declined in the area and recruited children aged six months to 10 years and low cut-off of parasite
density (250 asexual parasites/μl).
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decrement was not statistically significant [34].Safety profile of ACT reported in clinical trials conducted
in Tanzania
The safety of ACT was assessed by recording the nature
and incidence of solicited and unsolicited adverse events
and serious adverse events. An adverse event was de-
fined as any undesirable medical occurrence (symptoms,
signs or laboratory findings) in a patient during the
study regardless of whether it was related to the treat-
ment. Adverse events were judged according to their
causal association with ACT (unlikely, possible and
probable) and severity (mild, moderate or severe) [33].
Cough was the most common adverse event among chil-
dren treated with AL, while severe malaria was the most
reported serious adverse event requiring hospitalization
among children treated with AL or AS + AQ (Table 4).Other adverse events (as summarized in Table 4) were
mild and not directly attributed to the treatment.
Discussion
Following the recent reports of emergence of P. falcip-
arum artemisinin-resistant field isolates in Southeast
Asia [1,2,19] and the threat of such parasites spreading
to other malaria-endemic countries, country-specific evi-
dence based on reliable data are urgently required to
monitor the efficacy of the drugs and support timely re-
view and implementation of malaria treatment guide-
lines. Surveillance of anti-malarial efficacy is crucial to
enable early detection of emergence of drug resistance
when it happens before it spreads in most of the popu-
lations, as happened for CQ and SP [33]. Information
generated from such surveillance provides evidence to
relevant national and international authorities for pol-
icy formulation and review. This review was undertaken
to assess the implementation of efficacy testing for
Figure 2 Map of Tanzania showing the location at which the reviewed studies were conducted.
Table 2 Treatment outcome reported in efficacy trials in
Tanzania
Study ID Day-28 PCR-corrected % cure rate (95% CI)
TZ001_AL 97.0 (NR)
TZ001_AS + AQ 91.0 (NR)
TZ002_ AL 97.2 (NR)
TZ002_ AS + AQ 88.8 (NR)
TZ003_ AL 100.0 (NR)
TZ003_ AS + AQ 93.8 (NR)
TZ004_ AL 91.0 (NR)
TZ004_ AZ + AS 68.0 (NR)
TZ005_ AL 98.8 (95.5-99.7)
TZ005*_ AL 98.2 (94.5-99.4)
TZ006_ AL 95.1 (91.4-97.7)
TZ007_ AL 96.0 (NR)
TZ008_ AL 100.0 (NR)
TZ009_ AL 100.0 (NR)
TZ005_AL was the same study split into supervised and unsupervised*arm.
95% CI = 95% Confidence interval;
NR = Not reported.
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of uncomplicated falciparum malaria in Tanzania before
and after policy changes (in 2006).
Apparently, due to limited resources, especially funding,
NMCPs in most endemic countries have not been able to
implement regular anti-malarial drug efficacy monitoring
at sentinel sites and there has been a strong call for re-
gional networks to facilitate the implementation [42]. The
former East African Network for monitoring anti-malarial
treatment (EANMAT) forged a partnership between the
ministries of health and the research community in East
African countries and facilitated monitoring of anti-
malarial drug resistance in the region [28]. However, EAN-
MAT collapsed as a result of many factors, including de-
pendence on short-term donor funding.
The findings of this review showed that nine clinical
trials have been conducted to monitor the efficacy of
ACT before and after Tanzania adopted ACT for treat-
ment of uncomplicated malaria. Of these, only one study
[39] was conducted within the in vivo efficacy testing
framework of Tanzania NMCP/EANMAT with financial
support from NMCP and EANMAT. This might be
partly due to lack of funding, or due to complacency
attributed to perceived high therapeutic efficacy of
ACT. However, in Tanzania, NMCP-supported TETs
have resumed since 2011, although the findings have
not yet been published.
Table 3 Fever and parasite clearance in efficacy trials in Tanzania
Study ID Fever clearance by D1 (%) Day 1 Parasitaemic (%) Day 2 Parasitaemic (%) Day 3 Parasitaemic (%)
TZ001_AS + AQ 79.0 66.0 10.0 0
TZ001_AL 67.0 83.0 10.0 0
TZ005_ AL 64.3 71.3 6.7 1.1
TZ007_ AL 95.0 32.0 11.7 0
TZ008_ AL 95.0 NR 0 0
TZ009_ AL 73.9 77.3 19.5 1.4
D1refers to day 1;
NR = Not reported.
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which is the first-line anti-malarial drug for treatment of
uncomplicated falciparum malaria in Tanzania, was high
even after unsupervised treatment. The PCR-corrected
cure rate on day 28 was >91% and this is in line with
findings from other studies in eastern Africa [43,44].
The high cure rate (100%) reported in Muheza in 2004
[39] prior to the official adoption of AL was similar to
the cure rate reported in other African countries [45,46].
The efficacy of AS + AQ, which is currently the first-line
anti-malarial drug for treatment of uncomplicated falcip-
arum malaria in Zanzibar (an island part of the United
Republic of Tanzania) [30], was also high although com-
parably lower than that of AL (PCR-corrected cure rate
was 88.8 - 93.8% for AS + AQ compared to 91 -100% for
AL). The lower cure rates of AS + AQ compared to AL
could be attributed to the fact that AQ had been exten-
sively used in the country and was also adopted as a
second-line anti-malarial drug together with SP (whichTable 4 Adverse events reported in efficacy trials in Tanzania










Gastrointestinal complaints (5.3%), vomiting (1.5%), dermatologic
(including itching) (3.0%), respiratory (including respiratory infect
(15.9%), dizziness (0.8%), convulsions (2.3%)
TZ004_
AZ + AS
Gastrointestinal complaints (2%), vomiting (7.6%), dermatological
(including itching) (5.4%), respiratory tract respiratory infections
(11.6%), dizziness (1.6%), convulsions (0.8%)
TZ005_
AL
Severe malaria (4%), vomiting (1%), cough (10%), abdominal pain
(1%), diarrhoea (3%), weakness (1%), upper respiratory tract
infections (22%), skin infections (9%), urinary tract infection (5%),
otitis media (4%), tonsillitis (2%), conjunctivitis (4%), worm
infestation (1%), periodontitis (1%), asthma (0.3%)
TZ006_
AL
Severe malaria (1%), fever (34%), cough (34%), diarrhoea (12%)
TZ009_
AL
Cough (49.4%), fever (20.2%), abdominal pain (10.1%), diarrhoea
(1.3%), Headache (1.3%), skin rashes (1.3%)was the first-line) in 2001 [25]. Since AQ resistance had
been reported in Tanzania [27,47], addition of an artemi-
sinin to AQ was unlikely to make a combination with
high therapeutic efficacy. Similar failure rates have been
reported in other SSA countries that used AQ exten-
sively prior to introduction of AS + AQ [48].
The cure rates of AQ +AS in the present review com-
pares well with those reported elsewhere in East Africa
whereby day-28 adequate clinical and parasitological re-
sponse (ACPR) in children treated with AS + AQ was
90.2% in Kenya [49], 90.3% in Rwanda [50] and 91.7% in
Uganda [51]. These rates were comparatively lower than
those of AL. However, AS + AQ was selected and is still
being used as the first-line anti-malarial in some coun-
tries when other factors apart from efficacy were consid-
ered. In Burundi, prior to policy changes, day-14 ACPR
in children treated with AS + AQ was reported to be
95.3% compared to 99.3% for AL. However, considering
other factors such as acceptability by users, adherenceComments
Not attributed to the treatment
Not attributed to the treatment
Not attributed to the treatment
al
ion)
Gastrointestinal complaints were likely to be attributed to the
drugs
Gastrointestinal complaints were likely to be attributed to the
drugs
Severe malaria was recorded as severe adverse event. The rest
were mild or moderate in severity
Severe malaria was recorded as severe adverse event. The rest
were mild or moderate in severity. None was considered related to
AL treatment
No serious adverse events. All the AEs were not related to the
treatment
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for treatment of uncomplicated falciparum malaria in
Burundi [10,12]. Similarly, Zanzibar adopted AS +AQ as
the first-line anti-malarial despite lower day-28 ACPR com-
pared to AL (97% versus 91% for AS +AQ) [30].
There is a concern about the limited post-treatment
prophylactic effects of both AL and AS + AQ in high
transmission areas. In fact in one trial, more than half of
the recruited patients had recurrent infections within
the 42-day follow-up period after treatment with AL.
However, the majority of recurrent infections were due
to re-infections which suggests that the partner drug
cannot give prolonged protection despite high thera-
peutic efficacy [36]. Similar high re-infections rates have
been reported in other high transmission areas in Africa
after AL treatment [43,52]. Studies that compared the ef-
ficacy of AL and AS + AQ showed a significantly lower
risk of re-infection after treatment with AL compared to
AS + AQ [30,40] suggesting that AL confers a longer
prophylactic effect than AS + AQ. The difference in
prophylactic effect of the two drugs could be attributed
to the longer half-life of lumefantrine compared to AQ.
Thus, the concentration of the active amodiaquine metab-
olite might be lower or completely absent when a re-
infection occurs compared to lumefantrine concentration.
This observation has also been reported elsewhere in Africa
where re-infection rates were higher after AS +AQ treat-
ment than after AL [48,53,54]. However, a recent study has
reported high level of resistance to lumenfatrine in the
Democratic Republic of Congo [55] that threatens the
therapeutic usefulness of AL and further monitoring is ur-
gently needed in all malaria-endemic countries where AL is
the first-line anti-malarial drug.
In most of the studies, a great majority of the recur-
rent infections were due to re-infections, when assessed
with a step-wise PCR genotyping protocol, which signi-
fies that the drugs are still efficacious and the high rates
of re-infections could only be attributed to high malaria
transmission. In terms of clinical practice, the high re-
infection rates are of great concern among clinicians.
Clinicians should be clearly guided on what to expect
and how to handle such cases with recurrent infections
within a period of three to eight weeks post-treatment.
The observed high re-infection rates after ACT treat-
ment underscores the importance of integrating treat-
ment with vector control interventions, including use of
long-lasting insecticide-treated nets so as to effectively
block malaria transmission and prevent recurrent infec-
tions [56].
The study which tested AZ + AS showed that the drug
had low efficacy (28 days ACPR = 68%) and could not be
considered a potential anti-malarial drug in Tanzania
and other malaria-endemic countries [41]. It is plausible
that since AZ is a common antibiotic in the treatment oftrachoma, the local parasites might have been exposed
to the drug leading to development of resistance [57].
This could have possibly compromised the efficacy of
AZ + AS combination. An alternative explanation for the
observed lower efficacy of AZ + AS compared to adults
in Asia is that the effective dose of AZ absorbed in
often-malnourished African children might not be suffi-
cient to achieve adequate cure rates. Malnourishment is
known to reduce drug absorption [8] and cure rates
among patients treated with different drugs. Further-
more, a recent review of AZ across continents for treat-
ing uncomplicated malaria revealed that AZ has low
efficacy as a monotherapy for treatment of uncompli-
cated malaria and when used in combinations with other
anti-malarials, it may need to be used at high doses
which may affect tolerability to the drug [58].
Measurement and reporting of parasite clearance on
day 3 after treatment with ACT is particularly import-
ant, as this is one of the first signals of emergence of
parasite tolerance/resistance to artemisinin [23]. In the
present review, two studies reported day-3 parasitaemic
cases of 1.1 and 1.4% after treatment with AL [36,38]
and the day 3 parasite positivity rates were lower than
what has been previously reported [21]. However, the
parasite positivity rate reported on day 2 in one of the
studies conducted in Muheza district with moderate
malaria transmission was higher than the rates reported
in previous studies [21]. Thus, more studies will be re-
quired to confirm these findings and their role in pos-
sible emergence of artemisinin resistance. Although the
proportion of patients with detectable parasitaemia on
day 3 serves as a simple measure of parasite clearance
time at the population level [21], it is often influenced
by the baseline parasite density and the timing of para-
site sampling, which can vary within and across studies.
On the contrary, parasite clearance half-life doesn’t depend
on baseline parasite density and is thus considered a more
reliable indicator of changes in parasite susceptibility to
artemisinin. Measurement of parasite clearance at six-,
eight- or 12-hourly intervals for the first 72 hours, as it is
currently recommended [59,60], provides a population
level profile and useful data of parasite sensitivity to arte-
misinin. More accurate estimates of parasite clearance
through frequent parasite counts are recommended
[59,60]. However, the studies reviewed in this article were
based on 24-hour sampling, which is not the recom-
mended method for assessing parasite clearance and detec-
tion of tolerance/resistance to artemisinins.
Artemisinins are known to be highly potent anti-malarial
drugs that are active against immature gametocytes and
are useful in the reduction of malaria transmission and
elimination/eradication agenda [61]. In clinical trials
reviewed in this paper, it was shown that in fact AL and
AS +AQ have potentials to reduce gametocyte carriage
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cytes from four on day-0 to 68 sexual parasites per 500 leu-
cocytes on day-2 post AL treatment, as reported in one of
the trials [34], needs to be further evaluated in the light of
changes in the parasite sensitivity to ACT. Gametocyte
clearance by ACT has also been documented by other
studies in East Africa [62] and elsewhere [63,64] where sig-
nificant reduction of gametocytes by day 14 after treatment
with AL or AS +AQ was observed, indicating the potential
advantages of ACT over non-artemisinin-based anti-
malarials.
It is well established that the efficacy of AL combin-
ation is strongly influenced by variations in the pharma-
cokinetics of lumefantrine among individuals [8]. The
maximum therapeutic cure rate is achieved when the
plasma drug concentration is adequately available for at
least six days [65]. Measurements of day-7 plasma lume-
fantrine levels are particularly important in unsupervised
trials as a measure of adherence to treatment, rather
than the use of questionnaires [66]. Day-7 lumefantrine
concentrations were significantly lower in unsupervised
patients suggesting lower adherence to the drug dosage
or fat intake advice. However these differences did not
affect the cure rates and high therapeutic efficacy was
achieved even in the unsupervised group, indicating that
the parasites are highly susceptible to lumefantrine. The
observation by other studies in East Africa which
showed the median lumefantrine levels were significantly
lower in unsupervised patients, but without any effects
on the cure rates [67,68], lends support to the findings
of this review. It is clear that a high day-28 AL cure rate
can be achieved despite low plasma lumefantrine levels,
even among unsupervised patients. However care should
be taken to avoid exposure of parasites to sub-therapeutic
levels of the drugs and creating favourable conditions for
emergence of lumefantrine resistance [69]. Monitoring of
lumefantrine tolerance/resistance should also be imple-
mented in order to safeguard usefulness of AL.
The present review showed no unexpected adverse
events and overall, AL, AS + AQ and AZ + A were well
tolerated. Admittedly, the few studies that reported
safety profile in the present review (e.g., only one study
reported safety data on AS + AQ while the rest reported
AL safety) would not enable a firm comparison of safety
of different anti-malarials. However, other studies in
Africa have shown that certain mild or moderate ad-
verse events, such as vomiting and anaemia, were more
frequent in patients treated with AS + AQ than those
treated with AL [70,71]. This review has shown that re-
spiratory infection, including cough, was the most fre-
quent adverse event in children treated with AL. This is
in line with previous findings which showed that re-
spiratory infections were common in African children
with malaria [72,73]. The findings from a recent reviewon the safety of AL with other ACT in children [73]
showed that adverse events were attributed to symp-
toms or progression of malaria and not directly to the
drugs, and this lends support to the findings of this re-
view. Thus, AL and AS + AQ are safe when used for
treatment of uncomplicated malaria.
Limitation of the review
This review was meant to assess the implementation of
the WHO recommendations of undertaking regular moni-
toring of antimalarial efficacy studies and also provide
Tanzania-specific current efficacy and safety profile of
ACT in the treatment of uncomplicated falciparum mal-
aria. The review was limited to peer-reviewed publica-
tions, thus unpublished data were not included. However
the review highlighted the levels of implementation of
TETs in Tanzania and provides an overall country-specific
performance of ACT after their wide-scale deployment as
first-line anti-malarials for treating uncomplicated P. fal-
ciparum malaria in the country.
Future studies
Following the emergence of artemisinin resistance in
Southeast Asia, manifested as delayed clearance of P. fal-
ciparum after treatment with artemisinins, the demand
for tracking parasite sensitivity to artemisinin and its de-
rivatives has become more important. More accurate es-
timates of parasite clearance measurements through
frequent parasite counts (at least twice daily) to assess
delayed parasite clearance should be adopted in future
therapeutic efficacy testing studies [59,60]. However
these changes have significant cost and logistic implica-
tions that must be addressed.
Given the recent documentation of K13-propeller
polymorphism as a molecular marker for monitoring
resistance of artemisinin and its derivatives [22] and
despite absence of Asian mutant genotypes in SSA [74],
future efficacy studies should incorporate assessment of
this marker as a tool to track parasite tolerance or any
changes in parasite sensitivity to ACT [75]. Further-
more, the recent report of high resistance to lumefan-
trine should also be assessed in both in vivo and
in vitro studies. More importantly, optimization and
testing of other methods for resistance surveillance
such as ex-vivo and ring stage assay should be consid-
ered for future studies in SSA.
Conclusion
The present review has shown that few studies have
been conducted in Tanzania to monitor the efficacy and
safety of ACT and majority of these were not done
under the NMCP framework. However, the findings re-
vealed that the efficacy AL and AS + AQ was reasonably
high and the drugs were safe when used for treatment of
Shayo et al. Malaria Journal  (2015) 14:135 Page 10 of 12uncomplicated P. falciparum infections in Tanzania.
These findings support continued use of AL and AS +
AQ for the treatment of uncomplicated malaria in
Tanzania mainland and Zanzibar, respectively. Although
currently there is no evidence of artemisinin resistance
in Africa, regular monitoring and surveillance, as rec-
ommended by the WHO-supported GPARC must be
implemented so that the emergence of artemisinin re-
sistance in African can be timely detected, reported and
contained. More surveillance and monitoring of anti-
malarial efficacy and safety should be performed to de-
tect future changes in parasite sensitivity to ACT.
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